| March
5, 2007--BioCryst
Pharmaceuticals and Shionogi & Co. have entered into
an exclusive license agreement to develop and
commercialize BioCryst's lead influenza neuraminidase
inhibitor, peramivir, in Japan for the treatment of
seasonal and potentially life-threatening human influenza.
Under the terms of the
agreement Shionogi will obtain rights to injectable
formulations of peramivir in Japan in exchange for a $14
million up-front payment. BioCryst may also receive future
milestone payments totaling up to $116 million in addition
to double-digit royalty payments on product sales of
peramivir.
BioCryst retains all
rights to commercialize peramivir in North America,
Europe, and other countries outside of Japan and Korea. PR
Newswire
|
